Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: Preliminary report

Molecular Biology Reports

Volumn 41, Issue 5, 2014, Pages 2851-2857

  Kolacinska, Agnieszka ^a   Morawiec, Jan ^a,b   Fendler, Wojciech ^b   Malachowska, Beata ^b   Morawiec, Zbigniew ^a   Szemraj, Janusz ^b   Pawlowska, Zofia ^b   Chowdhury, Dipanjan ^c   Choi, Young Eun ^c   Kubiak, Robert ^b   Pakula, Lukasz ^a   Zawlik, Izabela ^d  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

Breast cancer; microRNA; Pathologic response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; MICRORNA; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORE BIOPSY NEEDLE; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE PERIOD; RNA ANALYSIS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; ADJUVANT THERAPY; CANCER GRADING; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PREOPERATIVE PERIOD; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84905689211     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3140-7     Document Type: Article

References (18)

1. Piccart MJ (2012) Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial. Ann Oncol 23(Suppl 6):vi5-6
2. Von Minckwitz G, Martin M (2012) Neoadjuvant treatments for triple negative breast cancer. Ann Oncol 23(Suppl 6):vi5-6
3. Von Minckwitz G, Untch M, Loibl S (2013) Update on neoadjuvant/ preoperative therapy of breast cancer: experiences from the German Breast Group. Curr Opin Obstet Gynecol 25:66-73
4. Von Minckwitz G, Untch M, Biohmer JU, Costa SD, Eidtmann H et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804
5. Ellis MJ, Perou CM (2013) The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 3:27-34
6. Balic M, Schwarzenbacher D, Stanzer S, Heitzer E, Auer M et al (2013) Genetic and epigenetic analysis of putative breast cancer stem cell models. BMC Cancer 13:358. doi:10.1186/1471-2407-13-358
7. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C et al (2013) The shaping and functional consequences of the microRNA landscapes in breast cancer. Nature 497:378-382
8. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E et al (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118:2603-2614
9. Tryndyak VP, Brland FA, Pogribny IP (2010) E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotype in human breast cancer cells. Int J Cancer 126:2575-2583
10. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127:1785-1794
11. Almog N, Ma L, Schwager C, Brinkmann BG, Beheshti A, Vajkoczy P (2012) Consensus microRNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS ONE 7:e44001. doi:10.1371/journal.pone.0044001
12. Almog N, Briggs C, Beheshti A, Ma L, Wilkie KP et al (2013) Transcriptional changes induced by the tumor dormancy-associated microRNA 190. Transcription 4 [Epub ahead of print]
13. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C et al (2011) Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer 10:52. doi:10.1186/1476-4598-10-52
14. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422 (Pubitemid 350013847)
15. Von Minckwitz G, Schmitt W, Loibl S, Muller BM, Blohmer JU et al (2013) Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-3628
16. Sun L, Yao Y, Lin B, Lin Z, Lin L et al (2012) MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31:432-445
17. Rutnam ZJ, Yang BB (2012) The non-coding 3′UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci 125:2075-2085
18. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY et al (2013) Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-3401